RARE
PHARMACEUTICAL PREPARATIONSUltragenyx Pharmaceutical Inc. - Common Stock (RARE) [ST]
www.ultragenyx.com ↗▲ 1.18%
prev close
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-07-15 | RAREUltragenyx Pharmaceutical Inc. - Common Stock | Buy | $1,001 - $15,000 | 247d ago | — |
2025-07-15
Gilbert Cisneros
RARE
Amount
$1,001 - $15,000
Filed
247d ago
Recent News
Powered by Polygon.io
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPC
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-07-15 · Purchase
$1,001 - $15,000